Daehan New Pharm Co. Ltd (054670) - Total Liabilities

Latest as of September 2025: ₩122.10 Billion KRW ≈ $82.74 Million USD

Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has total liabilities worth ₩122.10 Billion KRW (≈ $82.74 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Daehan New Pharm Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Daehan New Pharm Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Daehan New Pharm Co. Ltd to evaluate short-term liquidity relative to the company's equity base.

Daehan New Pharm Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Dae Young Pkg
KO:014160
Korea ₩72.47 Billion
Regal Holding Co Ltd
TW:4807
Taiwan NT$940.14 Million
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
India Rs3.48 Billion
YES24 Co.Ltd
KQ:053280
Korea ₩312.48 Billion
Inv Tricahue
SN:TRICAHUE
Chile CL$9.99 Billion
ESTsoft Corp
KQ:047560
Korea ₩120.13 Billion
RTG Mining Inc
TO:RTG
Canada CA$2.17 Million
Shagrir Group Vehicle Services Ltd
TA:SHGR
Israel ILA343.78 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Daehan New Pharm Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 054670 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.61 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.94 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.49 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Daehan New Pharm Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Daehan New Pharm Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Daehan New Pharm Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩95.85 Billion
≈ $64.95 Million
+41.84%
2023-12-31 ₩67.57 Billion
≈ $45.79 Million
+1.76%
2022-12-31 ₩66.40 Billion
≈ $45.00 Million
-11.68%
2021-12-31 ₩75.18 Billion
≈ $50.95 Million
-1.01%
2020-12-31 ₩75.95 Billion
≈ $51.47 Million
+13.62%
2019-12-31 ₩66.84 Billion
≈ $45.30 Million
+1.80%
2018-12-31 ₩65.66 Billion
≈ $44.49 Million
-6.33%
2017-12-31 ₩70.09 Billion
≈ $47.50 Million
+17.77%
2016-12-31 ₩59.52 Billion
≈ $40.33 Million
+7.38%
2015-12-31 ₩55.43 Billion
≈ $37.56 Million
-2.03%
2014-12-31 ₩56.58 Billion
≈ $38.34 Million
--

About Daehan New Pharm Co. Ltd

KQ:054670 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$55.36 Million
₩81.69 Billion KRW
Market Cap Rank
#21580 Global
#1271 in Korea
Share Price
₩5820.00
Change (1 day)
-0.34%
52-Week Range
₩5600.00 - ₩7840.00
All Time High
₩21012.38
About

Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more